Swedish biopharmaceutical firm Hansa Medical has begun dosing patients in its Phase II clinical trial of drug candidate IgG degrading enzyme of Streptococcus pyogenes (IdeS), to treat patients with severe anti-GBM antibody disease / Goodpasture’s disease.

IdeS is currently being developed to allow kidney transplantation in sensitised patients and is said to quickly and effectively reduce IgG antibodies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The investigator-initiated, open-label Phase II trial will evaluate the safety and tolerability of IdeS in 15 patients on standard care with pulse methylprednisolonene, oral prednisolone and intravenous cyclophosphamide (CYC) in combination with plasma exchange (PLEX).

The efficacy of the drug candidate will be further examined through analysis of renal function at six months post-treatment.

"IdeS is currently being developed to allow kidney transplantation in sensitised patients and is said to quickly and effectively reduce IgG antibodies."

Set to be conducted at 15 clinical sites in Europe, the Phase II trial will be led by Linköping University Hospital professor Mårten Segelmark.

See Also:

Efficacy data reported from three prior Phase II trials of IdeS demonstrated a rapid and significant decrease in anti-HLA antibodies, facilitating transplantation in patients who previously could not undergo the surgery because of the presence of anti-HLA IgG antibodies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The drug candidate is being further assessed in a multi-centre clinical trial in the US in highly sensitised patients who did not respond to existing desensitisation methods.

The results from the US trial are expected to be available next year.

It is expected that aside from transplantation, IdeS has applications in other solid organ transplants and various autoimmune diseases.